Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Formulation of sustained-release matrix tablets of nifedipine

니페디핀 서방성 정제의 제제설계

  • 최옥 (성균관대학교 약학대학) ;
  • 김승수 (성균관대학교 약학대학) ;
  • 박은석 (성균관대학교 약학대학) ;
  • 지상철 (성균관대학교 약학대학)
  • Published : 2002.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

Matrix tablets of nifedipine (NP) were prepared with Eudragit, diluent (lactose or Ca. phosphate) and Mg. stearate employing two different preparation methods (wet granulation and direct compression) to develop its sustained-release dosage forms. The effects of various formulation factors on the dissolution rate of the drug were investigated. Dissolution test was studied in pH 6.8 phosphate buffer containing 1% sodium lauryl sulfate using the paddle method. Formulation factors were the type and content of Eudragit, the type of diluent and the tablet preparation method. The optimum formula of NP matrix tablet, which resulted in a similar dissolution profile to that from Adalat Oros used as a reference, was 30 mg NP, 10% Eudragit RS, 2% Mg. stearate and an adequate quantity of lactose to yield 500 mg weight using the wet granulation method.

Keywords

References

  1. N. Kohri, K. Miyazaki, T. Arita, H. Shimono, A. Nomura and H. Yasuda, Release characteristics of nifedipine sustained-release granules in vitro and in healthy subjects, Chem. Pharm. Bull., 35, 2504-2509 (1987) https://doi.org/10.1248/cpb.35.2504
  2. L.A. Syed, Nifedipine, Analytical Profiles of Drug Substances, 18, 221-288 (1989)
  3. C.H. Kleinbloesem, P. Brummelen, J.A. Linde, P.J. Voogd and D.D. Breimer, Nifedipine: Kinetics and dynamics in healthy subjects, Clin. Pharmacol. Ther., 35, 742-749 (1984) https://doi.org/10.1038/clpt.1984.105
  4. D. Murdoch and R.N. Brogden, Sustained release nifedipine formulations, Drugs, 41, 737-779 (1991) https://doi.org/10.2165/00003495-199141050-00006
  5. G. Yan, H. Li, R. Zhang and D. Ding, Preparation and evaluation of a sustained-release formulation of nifedipine HPMC tablets, Drug Dev. Ind. Pharm., 26, 681-686 (2000) https://doi.org/10.1081/DDC-100101284
  6. S.E. Leucuta, The kinetics of nifedipine release from porous hydrophilic matrices and the pharmacokinetics in man, Die Pharmazie, 43, 845-848 (1988)
  7. Z. Wang, T. Horikawa, F. Hirayama and K. Uekama, Design and in vitro evaluation of a modified-release oral dosage form of nifedipine by hybriation of hydroxypropyl-beta-cyclodextrin and hydroxypropylcellulose, J. Pharm. Pharmacol., 45, 942-946 (1993) https://doi.org/10.1111/j.2042-7158.1993.tb05631.x
  8. K. Tateshita, S. Sugawara, T. Imai and M. Otagiri, Prepara- tion and evaluation of a controlled-release formulation of nifedipine using alginate gel beads, Bio. Pharm. Bull., 16, 420-424 (1993) https://doi.org/10.1248/bpb.16.420
  9. T. Chandy and C.P. Sharma, Chitosan beads and granules for oral sustained delivery of nifedipine: in vitro studies, Biomaterials, 13, 949-952 (1992) https://doi.org/10.1016/0142-9612(92)90119-9
  10. G.J. Filipovic, L.M. Becirevic, N. Skalko and I. Jalsenjak, Chitosan microsheres of nifedipine and nifedipine-cyclo- dextrin inclusion complexes, Int. J. Pharm., 135, 183-190 (1996) https://doi.org/10.1016/0378-5173(96)04470-5
  11. S.E. Leucuta, Controlled release of nifedipine from gelatin microspheres and microcapsules: in vitro kinetics and pharmacokinetics in man, J. Microencapsul., 7, 209-217 (1990) https://doi.org/10.3109/02652049009021834
  12. A. Barkai, Y.V. Pathak and S. Benita, Polyacrylate (Eudragit retard) microspheres for oral controlled release of nifedipine. I. Formulation design and process optimization, Drug Dev. Ind. Pharm., 16, 2057-2075 (1990) https://doi.org/10.3109/03639049009023640
  13. K.P.R. Chowdary and S.G. Girija, Eudragit microcapsules of nifedipine and its dispersions in HPMC-MCC : Physicochemi- cal characterization and drug release studies, Drug Dev. Ind. Pharm., 23, 325-330 (1997) https://doi.org/10.3109/03639049709149811
  14. W.H. Chuo, T.R. Tsai, S.H. Hsu and T.M. Cham, Preparation and in-vitro evaluation of nifedipine loaded albumin micro- spheres cross-linked by different glutaraldehyde concentra- tions, Int. J. Pharm., 144, 241-245 (1996) https://doi.org/10.1016/S0378-5173(96)04742-4
  15. M.R. Jenquin, S.M. Liebowitz, R.E. Sarabia and J.W. Mc- Ginity, Physical and chemical factors influencing the release of drugs from acrylic resin films, J. Pharm. Sci., 79, 811-816 (1990) https://doi.org/10.1002/jps.2600790914
  16. L. Maggi, M.L. Torre, P. Giunchedi and U. Conte, Suprami- cellar solutions of sodium dodecyl sulphate as dissolution media to study the in vitro release characteristics of sustained-release formulations containing an insoluble drug: nifedipine, Int. J. Pharm., 135, 73-79 (1996) https://doi.org/10.1016/0378-5173(95)04352-7
  17. F. Carli, G. Capone, I. Colombo, L. Magarotto and A. Motta, Surface and transport properties of acrylic polymers influen- cing drug release from porous matrices, Int. J. Pharm., 21, 317-329 (1984) https://doi.org/10.1016/0378-5173(84)90190-X
  18. J.W. Moore and H.H. Flanner, Mathematical comparison of dissolution profiles, Pharm. Tech., 20, 64-74 (1996)
  19. P.R.P. Vera and V. Banu, Sustained release of theophylline from Eudragit RLPO and RSPO tablets, Drug Dev. Ind. Pharm., 22, 1243-1247 (1996) https://doi.org/10.3109/03639049609063244
  20. R. Bodmeier, X. Guo, R.E. Sarabia and P.F. Skultety, The influence of buffer species and strength on diltiazem HCl release from beads coated with the aqueous cationic polymer dispersions, Eudragit RS, RL 30D, Pharm. Res., 13, 52-56 (1996) https://doi.org/10.1023/A:1016021115481